Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clodronic acid

Drug Profile

Clodronic acid

Alternative Names: 177501; Ascredar; Bonefos; Bonephos; CL-I.A.; Cl2MDP; Clasteon; Clastoban; Climaclod; Clodeosten; Clodron; Clodron beta; Clodronate; Clodronate disodium; Clody; Difosfonal; Dolkin; Hemocalcin; KCO 692; Lodronat; Loron; Lytos; Mebonat; Moticlod; Nikclod; Ossiten; Ostac; Osteonorm; Osteostab; Sindronat; ZK 00091106

Latest Information Update: 07 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering Oy
  • Developer Abiogen Pharma; Bayer HealthCare Pharmaceuticals; Roche; Schering Oy
  • Class Antihypercalcaemics; Antirheumatics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Collagen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases; Malignant hypercalcaemia; Postmenopausal osteoporosis
  • Phase II Osteoarthritis

Most Recent Events

  • 14 Mar 2019 Phase-II clinical trials in Osteoarthritis in Czech Republic (Intra-articular) (EudraCT 2018-002081-39)
  • 24 Jun 2018 Biomarkers information updated
  • 17 Jan 2018 No development reported - Phase-III for Osteoarthritis in Italy (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top